Literature DB >> 35697401

Updates in Pharmacologic Strategies in Adult Attention-Deficit/Hyperactivity Disorder.

Deepti Anbarasan1, Gabriella Safyer2, Lenard A Adler3.   

Abstract

Attention-deficit/hyperactivity disorder (ADHD) significantly worsens quality of life and long-term functional outcomes in adults. Individual impairments in adults with ADHD can be further contextualized within considerable costs to society at large. Food and Drug Administration (FDA) approved stimulants and nonstimulant medications can significantly improve ADHD symptoms in adults. In the past 2 decades, the United States FDA has expanded approval of pharmacotherapeutic options for adult ADHD. However, limitations still persist in available psychotropics for certain patient populations such as those with comorbid substance use or cardiovascular illness. Clinicians therefore must appreciate several ongoing investigations into medications with unique mechanisms of action. This article reviews the current FDA approved and emerging medication options while providing guidelines for pharmacologic management of adult ADHD.
Copyright © 2022 Elsevier Inc. All rights reserved.

Entities:  

Keywords:  ADHD medications; ADHD treatment; Adult ADHD; Attention; Hyperactivity

Mesh:

Substances:

Year:  2022        PMID: 35697401     DOI: 10.1016/j.chc.2022.03.008

Source DB:  PubMed          Journal:  Child Adolesc Psychiatr Clin N Am        ISSN: 1056-4993


  1 in total

1.  Editorial: Each child with ADHD is unique: Treat the whole patient, not just their symptoms.

Authors:  Edmund J S Sonuga-Barke; Salman Zubedat; Essam Daod; Iris Manor
Journal:  Front Behav Neurosci       Date:  2022-10-04       Impact factor: 3.617

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.